| |
| The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors. |
| |
|
|
| Abstract Details |
 |
|
| |
| |
| |
|
|
| |
Provisional Guidance on the Use of Hepatitis C Virus Protease Inhibitors for Treatment of Hepatitis C in HIV-Infected Persons |
|
|
|
|
| |
Thomas DL, Bartlett JG, Peters MG, Sherman KE, Sulkowski MS, Pham PA. Clin Infect Dis. 2011 Dec 14. [Epub ahead of print] |
|
| |
|
|
| |
Source Department of Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland.
In May 2011, hepatitis C virus (HCV) protease inhibitors (PIs) were approved by the US Food and Drug Administration to treat persons with genotype 1 chronic hepatitis C virus (HCV) infection, but not those dually infected with human immunodeficiency virus (HIV). Although critical safety and efficacy data are lacking, the availability of the drugs and substantial medical need justify the off-label use of HCV PIs in select HIV/HCV-coinfected persons. Pending results of ongoing investigations, this article represents provisional guidance on the use of HCV PIs in HIV-infected persons.
|
|
|
|
| |
| |
|
